|Application ||WB, LCI|
|Calculated MW||125991 Da|
|Homology||Rat - 15/16 amino acid residues identical. Human - not recommended for use with human samples.|
|Other Names||Voltage-dependent calcium channel subunit alpha-2/delta-4, Voltage-gated calcium channel subunit alpha-2/delta-4, Voltage-dependent calcium channel subunit alpha-2-4, Voltage-dependent calcium channel subunit delta-4, Cacna2d4|
|Related products for control experiments||Control peptide antigen (supplied with the antibody free of charge).|
|Target/Specificity||Peptide (C)SERPQEMGRLLGEADG, corresponding to amino acid residues 881-896 of mouse Cav־±2־´4 (Accession Q5RJF7). Extracellular.|
|Peptide Confirmation||Confirmed by mass-spectrography and amino acid analysis.|
|Format||Affinity purified antibody, lyophilized powder|
|Reconstitution||50 µl or 0.2 ml deionized water, depending on the sample size.|
|Antibody Concentration After Reconstitution||0.8 mg/ml.|
|Storage Before Reconstitution||Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.|
|Storage After Reconstitution||The reconstituted solution can be stored at 4ºC for up to 2 weeks. For longer periods, small aliquots should be stored at -20ºC or below. Avoid multiple freezing and thawing. The further dilutions should be made using a carrier protein such as BSA (1%). Centrifuge all antibody preparations before use (10000 × g 5 min).|
|Control Antigen Storage Before Reconstitution||Lyophilized powder can be stored intact at room temperature for several weeks. For longer periods, it should be stored at -20°C.|
|Control Antigen Reconstitution||100 µl DDW.|
|Control Antigen Storage After Reconstitution||-20ºC.|
|Preadsorption Control||1 µg peptide per 1 µg antibody.|
|Formulation||Lyophilized powder. Reconstituted antibody contains phosphate buffered saline (PBS), pH 7.4, 1% BSA, 0.05% NaN3.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Voltage-gated Ca2+ (CaV) channels are ubiquitously expressed and function as Ca2+ conducting pores in the plasma membrane1. Based on their electrophysiological and pharmacological properties, Ca2+ channels have traditionally been classified into L, T, N, P, Q, and R types2. L-type calcium channels are heteromultimers composed of four independently encoded proteins, the pore-forming α1 subunit, which triggers Ca2+ flow across the membrane, and the auxiliary subunits α2δ, γ, and β3. The Ca2+ channel α2δ subunit is a heavily glycosylated protein that is encoded by a single gene and post-translationally cleaved to yield α2 and δ subunits linked by a disulfide bond with a single transmembrane segment4. The α2δ subunit regulates many functional aspects of Ca2+ channels, such as gating, regulating voltage dependent kinetics, and increasing functional channel density on the plasma membrane5. There are four proteins that comprise CaVα2δ: CaVα2δ1, CaVα2δ2, CaVα2δ3 and CaVα2δ46. CaVα2δ4 participates in the regulation of membrane expression of CaV channels. It is predominantly expressed in certain types of endocrine cells. It is also detected in the erythroblasts in the fetal liver, in the cells of the zona reticularis of the adrenal gland and in the basophiles of the pituitary7. Defects in CaVα2δ4 are the cause of retinal cone dystrophy 4 (RCD4). RCD4 is characterized by minimal symptoms except for slowly progressive reduction in visual acuity8.
References 1. Catterall, W.A. (2000) Annu. Rev. Cell. Dev. Biol. 16, 521. 2. Qin, N. et al. (2002) Mol. Pharmacol. 62, 485. 3. De Jongh, K.S. et al. (1990) J. Biol. Chem. 265, 14738. 4. Sipos, I. et al. (2000) Pflug. Arch. 439, 691. 5. Dolphin, A.C. (2009) Curr. Opin. Neurobiol. 19, 237. 6. Cooper C.L. et al. (1987) J. Biol. Chem. 262, 509. 7. Wycisk, K.A. et al. (2006) Invest. Ophthalmol. Vis. Sci. 47, 3523.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.